abstract |
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular cathepsins B, K, L, F and S, and are therefore useful in the treatment of diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and methods for their preparation. |